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ABSTRACT
Objectives To synthesise the available evidence on
pharmacological and non-pharmacological interventions
recommended for ﬁbromyalgia syndrome (FMS).
Methods Electronic databases including MEDLINE,
PsycINFO, Scopus, the Cochrane Controlled Trials Registry
and the Cochrane Library were searched for randomised
controlled trials comparing any therapeutic approach as
recommended in FMS guidelines (except complementary
and alternative medicine) with control interventions in
patients with FMS. Primary outcomes were pain and
quality of life. Data extraction was done using
standardised forms.
Results 102 trials in 14 982 patients and eight active
interventions (tricyclic antidepressants, selective
serotonin reuptake inhibitors, serotonin noradrenaline
reuptake inhibitors (SNRIs), the gamma-amino butyric
acid analogue pregabalin, aerobic exercise, balneotherapy,
cognitive behavioural therapy (CBT), multicomponent
therapy) were included. Most of the trials were small and
hampered by methodological quality, introducing
heterogeneity and inconsistency in the network. When
restricted to large trials with ≥100 patients per group,
heterogeneity was low and beneﬁts for SNRIs and
pregabalin compared with placebo were statistically
signiﬁcant, but small and not clinically relevant. For non-
pharmacological interventions, only one large trial of CBT
was available. In medium-sized trials with ≥50 patients
per group, multicomponent therapy showed small to
moderate beneﬁts over placebo, followed by aerobic
exercise and CBT.
Conclusions Beneﬁts of pharmacological treatments in
FMS are of questionable clinical relevance and evidence
for beneﬁts of non-pharmacological interventions is
limited. A combination of pregabalin or SNRIs as
pharmacological interventions and multicomponent
therapy, aerobic exercise and CBT as non-pharmacological
interventions seems most promising for the management
of FMS.
INTRODUCTION
Key symptoms of ﬁbromyalgia syndrome (FMS) are
chronic widespread pain associated with cognitive
dysfunction, sleep disturbances and physical
fatigue.1 2 Patients often report high levels of dis-
ability and poor quality of life, and an extensive use
of medical care.3 In the absence of suitable labora-
tory tests, diagnosis is established by a history of
key symptoms and the exclusion of somatic dis-
eases sufﬁciently explaining these symptoms.2 4
The estimated overall prevalence of FMS is 2.9% in
the general population of ﬁve European countries.5
The deﬁnite aetiology of FMS remains unknown.4
Since speciﬁc treatment aimed at altering the
pathogenesis is not possible, the therapeutic focus
is on symptom reduction.
Systematic reviews and evidence-based guidelines
provide healthcare professionals and patients with a
guide through the large variety of pharmacological
and non-pharmacological treatment options offered
to and used by patients with FMS.6 The American
Pain Society7 and the Association of Scientiﬁc
Medical Societies in Germany4 strongly recommend
a pharmacological intervention (amitriptyline) and
several non-pharmacological treatments (aerobic
exercise, cognitive behavioural therapy (CBT), mul-
ticomponent therapy). Conversely, the European
League Against Rheumatism (EULAR) have given
only a strong recommendation for a variety of
pharmacological therapies (eg, tricyclic antidepres-
sants (TCAs), serotonin-noradrenaline reuptake
inhibitors (SNRIs), serotonin reuptake inhibitors
(SSRIs), gamma-amino butyric acid analogues
(GABA) such as pregabalin) but weak recommenda-
tions for non-pharmacological therapies such as
aerobic exercise, CBT and multicomponent
therapy.8 Recommendations for ﬁrst-line treatment
options of FMS, however, are hampered by the lack
of head-to-head comparisons of pharmacological
versus non-pharmacological treatments.
Network meta-analyses allow a uniﬁed coherent
analysis of all randomised controlled trials compar-
ing pharmacological and non-pharmacological
treatments head-to-head or with a control inter-
vention, while fully respecting randomisation.9–11
We performed a systematic review with network
meta-analysis of randomised trials in patients with
FMS evaluating effects of pharmacological and
non-pharmacological interventions recommended
in FMS guidelines on pain and quality of life. We
provide an overall synthesis of available data that
can be used to guide treatment decisions and
examined the potential for bias due to methodo-
logical ﬂaws or small-study effects.12–15
METHODS
Literature search and trial selection
We searched MEDLINE, PsycINFO, Scopus, the
Cochrane Controlled Trials Registry and the
Cochrane Library, all from inception through
31 December 2011. The search strategy has been
previously described.16–21 We included treatment
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options approved by the Food and Drug Administration for
FMS or recommended by evidence-based guidelines on the
management of FMS:4 antidepressants, GABA-analogues,
aerobic exercise, balneotherapy, CBT and multicomponent ther-
apies (at least one exercise component and at least one psycho-
logical component). Therapeutic interventions were excluded if
they had been studied in fewer than four trials or were classi-
ﬁed as alternative and complementary medicine according to
National Institutes of Health (NIH) criteria (http://nccam.nih.
gov/health/whatiscam/). We included randomised controlled
trials in patients with FMS deﬁned according to established cri-
teria,22–24 comparing any of these pre-speciﬁed therapeutic
approaches with control interventions. Waiting list or treat-
ment as usual were classiﬁed as non-intervention control, drug
placebo or sham intervention as placebo control and interven-
tions deemed a priori to be only minimally active (such as
relaxation, education or passive physical therapy) as minimally
active control. No language restrictions were applied. Two
reviewers independently evaluated reports for eligibility and
contacted a third reviewer to resolve disagreements.
Outcomes
Pain and quality of life were pre-speciﬁed as primary outcomes
whereas the remaining key domains of FMS,25 sleep and
fatigue were speciﬁed as secondary outcomes. Drop-outs,
deﬁned as patients who terminated the trial early for any
reason during the treatment period, were extracted as a
measure of acceptability.11 When there was more than one
measure for a speciﬁc outcome, we gave preference to measures
recommended by OMERACT.25
Data extraction
We used standardised forms of previous reviews to extract data
on publication status, trial design, patients, characteristics and
treatment regimens16–19 and to assess components of methodo-
logical trial quality (generation of randomisation sequence, allo-
cation concealment, blinding of patients and handling of
incomplete outcome data; for deﬁnitions see Methods S1 in the
online supplement)12 26 independently by two reviewers.
Results of the outcomes at the end of the treatment period
were extracted by one reviewer (WH) and cross-checked by
another (EN). We contacted corresponding authors of trials
with incomplete outcome data. When necessary, means and
measures of dispersion were approximated from ﬁgures in the
reports.
Data synthesis
Whenever available we used results from intention-to-treat ana-
lyses. We expressed treatment effects as standardised mean dif-
ferences (SMD) by dividing the difference in mean values
between treatment groups at the end of treatment by the
pooled standard deviation. If information for the calculation of
pooled standard deviations was unavailable or ambiguous in a
trial, we used the median pooled standard deviation from other
trials using the same scale. Negative SMDs indicate a beneﬁcial
effect of the experimental intervention throughout. An SMD
of −0.20 indicates small differences between groups whereas
−0.50 suggests moderate and −0.80 large differences.27
Treatment effects for acceptability were expressed as risk ratios
of dropouts.
Details of the statistical methods used for meta-analysis are
provided in Methods S2 and S3 in the online supplement. In
short, we used Bayesian hierarchical random effects models
which fully preserve randomised treatment comparisons within
trials.10 28 29 Pooled SMDs or risk ratios comparing different
active and control interventions were estimated from the
median of the posterior distribution, corresponding 95% cred-
ibility intervals (95% CrI) from the 2.5th and 97.5th percen-
tiles. Credibility intervals can be interpreted similarly to
conventional CI. We examined heterogeneity between trials,
goodness of model ﬁt and inconsistency between direct and
indirect estimates30 31 and performed conventional Bayesian
random effects meta-analyses for all available direct
comparisons.32
For primary outcomes we drew funnel plots of trials compar-
ing any active intervention with non-intervention or placebo
controls,33 enhanced by contours dividing the plots into areas
of signiﬁcance and non-signiﬁcance at a two-sided p=0.05,34 35
and added lines of predicted treatment effects derived from uni-
variable random effects meta-regression models using the
standard error as explanatory variable.36 37 Funnel plot asym-
metry was assessed with Egger ’s test.38
We stratiﬁed analyses according to adequate generation of
random sequence, concealment of allocation, blinding,
intention-to-treat analysis, sample size and exclusion of
patients with inﬂammatory rheumatic disorders or mental dis-
orders and derived p values for interaction between trial charac-
teristics and treatment effect as previously described.39 40 We
pre-speciﬁed a cut-off of an average of 100 randomised patients
per treatment group to distinguish between small and large
trials.14 Since no large trials were available for most of the
interventions and there was evidence for small-study effects,
we explored the impact of trial size by a stepwise restriction of
the analysis to trials of increasing sample size, with cut-offs of
25, 50 and 100 patients per treatment arm; 2×25 patients will
yield more than 80% power to detect a large SMD of −0.80,
2×50 patients will yield more than 80% power to detect a
moderate to large SMD of −0.60, and 2×100 patients more
than 80% power to detect a small to moderate SMD of −0.40
at a two-sided α=0.05. Networks of pharmacological and non-
pharmacological treatments failed to connect at cut-offs of
2×50 and 2×100 patients. We therefore used differences
between non-intervention control and placebo observed in
overall analyses to connect the two networks through combin-
ation of placebo and non-intervention control groups.
RESULTS
Selection and characteristics of included trials
Figure 1 shows the ﬂowchart for the selection of randomised
trials in FMS. One hundred and two trials with 14 982 patients
were eligible and contributed to the network meta-analysis
(table 1 and supplementary online table S1). The trials included
a median of 69 randomised patients (range 14–1196) and were
published between 1986 and 2011. Fifteen trials evaluated
TCAs (1026 patients), 10 trials SSRIs (644 patients), 10 trials
SNRIs (5980 patients) and 4 trials the GABA analogue pregaba-
lin (2625 patients). Thirty-three trials evaluated aerobic exercise
(2266 patients), 9 trials balneotherapy (387 patients), 20 trials
CBT (1712 patients) and 15 trials multicomponent therapy
(1751 patients). Thirty-eight trials had a non-intervention
control (2689 patients), 40 trials had a placebo control (10 545
patients) and 23 trials had a minimally active control (2129
patients). Forty-two trials (41%) reported an adequate random-
isation schedule to allocate patients, 34 (33%) trials adequately
concealed treatment allocation, 35 (34%) reported adequate
blinding of patients and 20 (20%) reported analyses according
to the intention-to-treat principle. The average age of the
patients was 47 years, most were women and of Caucasian
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origin and had an average disease duration of 8.8 years. Figure 2
shows networks of analysed comparisons for the primary
outcomes.
Pain
Figure 3 (left) shows the effects on pain in 89 trials including
12 979 patients between active interventions and placebo.
Balneotherapy showed very large effects, SSRIs, aerobic exer-
cise, CBT and multicomponent therapy showed moderate to
large effects and TCAs, SNRIs and pregabalin showed small to
moderate effects compared with placebo. For all interventions,
95% CrIs did not overlap the null effect line. We found no clear
difference between non-intervention controls and placebo
(SMD 0.00, 95% CrI −0.31 to 0.30) but a small difference
between minimally active controls and placebo (SMD −0.22
favouring minimally active controls, 95% CrI −0.54 to 0.09).
Heterogeneity was high with an estimate of between-trial vari-
ance τ2 of 0.10 (95% CrI 0.06 to 0.17). Results of analyses
stratiﬁed according to methodological and clinical characteris-
tics of included trials are shown in supplementary online table
S2. Heterogeneity between trials was much reduced when
restricted to trials with adequate randomisation, allocation con-
cealment or patient blinding and large trials with at least 100
patients per arm, but there was no clear pattern for effects
depending on trial characteristics and tests for interaction
between effects and characteristics were all non-signiﬁcant
(p≥0.54).
The scatter of effect estimates and the prediction lines
observed in funnel plots for pain indicated asymmetry for both
pharmacological and non-pharmacological interventions, with
higher asymmetry for non-pharmacological interventions
(ﬁgure 4, upper panel). Figure 3 (middle and right) shows
results from network meta-analyses restricted to trials with
≥25 patients per group (53 trials, 11 746 patients), ≥50 patients
per group (25 trials, 9784 patients) and ≥100 patients per
group (14 trials, 8534 patients), respectively. In general, effects
compared with placebo became less pronounced with increas-
ing sample size of trials. The difference between balneotherapy
and placebo was reduced in trials with ≥25 patients only (SMD
−0.92, 95% CrI −1.60 to −0.26) and no trials with ≥50 patients
were available for this intervention. When the network was
restricted to trials with ≥50 patients per group the effects of
TCAs (SMD −0.32, 95% CrI −0.66 to 0.02), aerobic exercise
(SMD −0.37, 95% CrI −0.72 to −0.03) and CBT (SMD −0.32,
95% CrI −0.52 to −0.11) compared with placebo were reduced
to small to moderate differences. The effects of pregabalin and
Figure 1 Flowchart for the selection of randomised trials.
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multicomponent therapy were unaffected by the restriction.
Heterogeneity between trials decreased from τ2=0.10 in the
overall analysis to τ2=0.01 in the analysis restricted to ≥50
patients per group and, accordingly, the precision of estimates
increased. Only SNRIs, pregabalin and CBT were evaluated in
large trials with ≥100 patients per group and showed small to
moderate effects compared with placebo. Heterogeneity was
low with τ2 of 0.00 (95% CrI 0.00 to 0.03).
Quality of life
Funnel plots for quality of life indicated asymmetry for both
pharmacological and non-pharmacological interventions, again
with higher asymmetry for non-pharmacological interventions
(ﬁgure 4, bottom). Figure 5 shows results from the network
meta-analysis overall (78 trials, 12 283 patients) and after step-
wise restriction to trials with ≥25 patients per group (55 trials,
11 491 patients), ≥50 patients per group (26 trials, 9415
patients) and ≥100 patients per group (14 trials, 8120 patients).
In the overall network, moderate to large effects for quality of
life were found for all non-pharmacological interventions
whereas pharmacological interventions showed small to
moderate effects compared with placebo. Again we found no
clear difference between non-intervention controls and placebo
(SMD −0.13, 95% CrI −0.54 to 0.28) and a small to moderate
difference between minimally active controls and placebo
(SMD −0.34, 95% CrI −0.75 to 0.06). Heterogeneity between
trials was high with a τ2 estimate of 0.14 (95% CrI 0.08 to
0.23). Results of stratiﬁed analyses were similar to those
observed for pain except for a signiﬁcant interaction between
treatment effect and intention-to-treat analysis (p=0.016, see
supplementary online table S3).
In general, the effects became smaller with restrictions to
increasing sample size of trials and between-trial heterogeneity
decreased from τ2=0.14 in the overall analysis to τ2=0.00 in the
analysis restricted to ≥50 patients and ≥100 patients per group,
respectively. We found moderate effects for multicomponent
therapy (SMD −0.56, 95% CrI −0.76 to −0.36) after restriction
to trials with ≥50 patients per group, moderate effects for CBT
(SMD −0.60, 95% CrI −0.91 to −0.29) and small effects for
SNRIs (SMD −0.21, 95% CrI −0.29 to −0.14) and pregabalin
(SMD −0.21, 95% CrI −0.34 to −0.07) after restriction to trials
with ≥100 patients per group. All other interventions were not
signiﬁcantly different from placebo with 95% CrI overlapping
the null effect.
The results of network meta-analyses of secondary out-
comes, sensitivity analyses, model ﬁt and network consistency
are shown in supplementary online tables S4–S10.
DISCUSSION
In this systematic review and network meta-analysis of
pharmacological and non-pharmacological interventions includ-
ing 102 trials in 14 982 patients with FMS, most of the trials
were very small and hampered by low methodological quality.
We found evidence for small-study effects and high heterogen-
eity and inconsistency introduced by small trials. In network
meta-analyses restricted to moderate or large-sized trials, we
found advantages of pharmacological interventions over
placebo on pain and quality of life, which were either statistic-
ally non-signiﬁcant (SSRIs and TCAs) or of questionable clin-
ical relevance despite statistical signiﬁcance (SNRIs and
pregabalin). Among non-pharmacological interventions, multi-
component therapy followed by aerobic exercise and CBT was
most promising for reducing pain and improving quality of life.
Of the non-pharmacological interventions, only CBTwas eval-
uated in one large trial, for which it remained unclear whether
allocation was adequately concealed.41 In general, treatment
effects were slightly larger for pain than for quality of life.
To our knowledge, this is the ﬁrst network meta-analysis to
combine pharmacological and non-pharmacological interven-
tions in FMS. We could analyse effects of pharmacological and
non-pharmacological interventions reported in different trials
in a single model irrespective of the control intervention
used,42 which allowed us to estimate relative effects of two
interventions that have not been compared directly. This single
model assumes that relative treatment effects comparing two
interventions in different trials originate from a common distri-
bution. This, however, only holds in our networks restricted to
medium-sized and large trials where heterogeneity and incon-
sistency were low.
Our study is based on extensive literature searches and we
consider it unlikely that we have missed important trials.
Nevertheless, for some interventions we identiﬁed only small
trials of questionable methodological quality. Stepwise restric-
tion to trials with larger sample size led to decreases of
between-trial heterogeneity and network inconsistency and,
Table 1 Characteristics of included randomised trials
Characteristic
Total
(n=102)
Number of patients randomised, median (range) 69 (14–1196)
Number of multiarm trials, n (%) 28 (28%)
Year of publication, median (range) 2005 (1986–2011)
Mean duration of treatment, weeks, median (range) 12 (1–27)
Intervention evaluated (no. of trials/no. of randomised patients)
Tricyclic antidepressants 15/1026
Selective serotonin reuptake inhibitors 10/644
Serotonin noradrenaline reuptake inhibitors 10/5980
Pregabalin 4/2625
Aerobic exercise 33/2266
Balneotherapy 9/387
Cognitive behavioural therapy 20/1712
Multicomponent therapy 15/1751
Minimally active control 23/2129
Placebo 40/10545
Non-intervention control 38/2689
Outcome analysed (no. of trials/no. of analysed patients)
Pain 89/12979
Quality of life 78/12283
Fatigue 52/10145
Sleep 35/4298
Dropouts 102/14982
Methodological characteristics, no of trials (%)
Adequate generation of random sequence 42 (41%)
Adequate allocation concealment 34 (33%)
Adequate blinding of patients 35 (34%)
Intention-to-treat analysis performed 20 (20%)
Characteristics of patients
Patients with inflammatory rheumatic disorders excluded,
no of trials (%)
69 (68%)
Patients with mental disorders excluded, no. of trials (%) 48 (47%)
Percentage of Caucasians, median (range) 100 (65–100)
Percentage of females, median (range) 98 (63–100)
Average age, years, median (range) 47 (16–59)
Average disease duration, years, median (range) 8.8 (1.3–21.6)
Thirty-eight trials did not report the percentage of Caucasians, three trials did not
report the percentage of women, five trials did not report the average age of
included patients and 30 trials did not report the average disease duration.
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generally, to a decrease in estimated beneﬁts of interventions
compared with placebo. We consider the results of network
meta-analyses restricted to moderately-sized (≥50 patients per
trial arm) or large trials (≥100 patients per arm) more credible
than the overall analysis. However, the number of interventions
available in the network decreased and, of the non-
pharmacological interventions, only CBT remained in the
network of large trials, which we consider one of the most
important limitations. We deem estimates of CBT, balneother-
apy and SSRIs most problematic as beneﬁts changed by factors
Figure 2 Network of analysed comparisons in the network meta-analyses of the primary outcomes. Numbers denote numbers of trials (number of
analysed patients) per comparison for pain (normal type) and quality of life (italics). CBT, cognitive behavioural therapy; SNRIs, serotonin
noradrenaline reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
Figure 3 Estimates of standardised mean differences (SMDs) with 95% credibility intervals (95% CrI) in pain for therapeutic interventions compared
with placebo from overall network meta-analyses and network meta-analyses restricted to trials with ≥25, ≥50 and ≥100 patients per group and
corresponding between-trial heterogeneity variance estimates τ2 (95% CrI). Negative SMDs indicate beneﬁt of therapeutic interventions compared
with placebo. *Non-intervention control and placebo groups were combined to connect networks after correction for the SMD between
non-intervention control and placebo of 0.00. CBT, cognitive behavioural therapy; SNRIs, serotonin noradrenaline reuptake inhibitors; SSRIs, selective
serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
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of 2–3 after restrictions of networks to larger trials. Since a
moderate beneﬁt of CBT was estimated in a single large trial
with unclear allocation concealment,41 it is unclear whether
this beneﬁt can be conﬁrmed in future adequately powered
trials with appropriate design and conduct. Another limitation
of our study is that some interventions, although widely used
for the treatment of FMS in clinical practice (eg, tramadol),
were not included in our analysis because they were studied in
fewer than four trials.
The presence of small-study effects with large residual
between-trial heterogeneity after stratiﬁcation according to trial
characteristics resulted in low power of interaction tests and
non-signiﬁcant p values, and should be interpreted with
caution. Conversely, statistical and visual examination of
funnel plots indicated asymmetry suggestive of small-study
effects.15 Although true clinical heterogeneity may explain this
asymmetry,15 43 it is more plausible that asymmetry arises
from the cumulative effect of various biases at the level of
design, conduct, analysis and publication. As previously sug-
gested in the ﬁeld of osteoarthritis,14 sample size could there-
fore be viewed as a proxy for the cumulative effect of various
biases prevalent in randomised FMS trials.
In clinical practice, different effectiveness on key symptoms
of FMS other than pain and quality of life might lead to the
selection of a combination of various treatment modalities,
both pharmacological and non-pharmacological. However, we
did not ﬁnd any intervention for which there was conclusive
evidence for clinically relevant beneﬁts on our secondary out-
comes of fatigue, sleep disturbance or acceptability. Limited
data are available from randomised trials about other clinical
Figure 4 Contour-enhanced funnels plots for pain (top) and quality of life (bottom) comparing pharmacological (left) and non-pharmacological (right)
with non-intervention control or placebo. Numbers on the x-axis are standardised mean differences (SMDs) and numbers on the y-axis are standard
errors of SMDs. Areas of statistical signiﬁcance at p=0.05 are shown in grey and prediction lines from univariable meta-regression models with the
standard error as explanatory variable are shown in red. p Values are derived from regression tests for asymmetry.
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dimensions such as coping or patients’ beliefs, and we cannot
make any conclusions about these. The generalisability of our
ﬁndings derived from randomised trials to the clinical FMS
population is limited, especially by the participation of selected
FMS patients in randomised trials.16–21 44 Generalisability may
also be hampered by protocol mandated repetitive follow-ups
with extensive assessments and completion of multiple ques-
tionnaires. This would not be part of standard management
and may themselves be considered as management strategies.
A recently published network meta-analysis of licensed
dosages of pregabalin and the SNRIs duloxetine and milnacipran
found similar beneﬁts of these drugs over placebo on pain and
quality of life, with evidence comparably robust to our network
meta-analyses of large trials.45 Although statistically signiﬁcant,
differences in pain between pregabalin and placebo were
approximately 0.6 cm on a 10 cm visual analogue scale corre-
sponding to an SMD of 0.25.45 We consider the small advantages
of pregabalin and SNRIs over placebo of questionable clinical
relevance.40 Our results do not necessarily support EULAR
recommendations currently favouring drug therapy over other
treatment options.8 In our analysis restricted to moderate and
large-sized trials, we found potentially important beneﬁts of
aerobic exercise, CBT and multicomponent therapy in the
management of FMS, which is in line with recommendations
of the American Pain Society and the Arbeitsgemeinschaft
der Wissenschaftlichen Medizinischen Fachgesellschaften in
Germany.4 7
In conclusion, evidence about effective and clinically relevant
treatments for FMS is limited. Additional large-scale rando-
mised trials of high methodological quality of promising non-
pharmacological interventions such as CBT, aerobic exercise
and multicomponent therapy are warranted. In view of the cur-
rently available evidence, a combination of pregabalin or SNRIs
as pharmacological interventions and multicomponent therapy,
aerobic exercise or CBT as non-pharmacological interventions
seems most promising.
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